Publication:
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies

dc.contributor.authorPatchanee Chootongen_US
dc.contributor.authorFrancis B. Ntumngiaen_US
dc.contributor.authorKelley M. VanBuskirken_US
dc.contributor.authorJia Xainlien_US
dc.contributor.authorJennifer L. Cole-Tobianen_US
dc.contributor.authorChristopher O. Campbellen_US
dc.contributor.authorTresa S. Fraseren_US
dc.contributor.authorChristopher L. Kingen_US
dc.contributor.authorJohn H. Adamsen_US
dc.contributor.otherUniversity of South Florida, Tampaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherUniversity of Notre Dameen_US
dc.contributor.otherCase Western Reserve Universityen_US
dc.contributor.otherSeattle Biomedical Research Instituteen_US
dc.date.accessioned2018-09-24T09:07:44Z
dc.date.available2018-09-24T09:07:44Z
dc.date.issued2010-03-01en_US
dc.description.abstractPlasmodium vivax Duffy binding protein (DBP) is a merozoite microneme ligand vital for blood-stage infection, which makes it an important candidate vaccine for antibody-mediated immunity against vivax malaria. A differential screen with a linear peptide array compared the reactivities of noninhibitory and inhibitory high-titer human immune sera to identify target epitopes associated with protective immunity. Naturally acquired anti-DBP-specific serologic responses observed in the residents of a region of Papua New Guinea where P. vivax is highly endemic exhibited significant changes in DBP-specific titers over time. The anti-DBP functional inhibition for each serum ranged from complete inhibition to no inhibition even for high-titer responders to the DBP, indicating that epitope specificity is important. Inhibitory immune human antibodies identified specific B-cell linear epitopes on the DBP (SalI) ligand domain that showed significant correlations with inhibitory responses. Affinity-purified naturally acquired antibodies on these epitopes inhibited the DBP erythrocyte binding function greatly, confirming the protective value of specific epitopes. These results represent an important advance in our understanding of part of blood-stage immunity to P. vivax and some of the specific targets for vaccine-elicited antibody protection. Copyright © 2010, American Society for Microbiology. All Rights Reserved.en_US
dc.identifier.citationInfection and Immunity. Vol.78, No.3 (2010), 1089-1095en_US
dc.identifier.doi10.1128/IAI.01036-09en_US
dc.identifier.issn10985522en_US
dc.identifier.issn00199567en_US
dc.identifier.other2-s2.0-77349089144en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/29266
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77349089144&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleMapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodiesen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77349089144&origin=inwarden_US

Files

Collections